The main goal of the trial is to find out whether LY4268989 can bring more participants into clinical remission—periods when symptoms are absent or very mild—than the placebo during the first 10 weeks and to see if the benefit continues through a longer, 52‑week maintenance phase for those who respond early. Participants will start by taking the study tablets daily for about ten weeks (the induction phase). If they show improvement, they may continue the same treatment for up to a year (the maintenance phase), with regular visits to check how they are doing.

During the study, doctors will use a scoring system called the Modified Mayo Score to decide whether a person has reached remission; this score looks at stool frequency, bleeding, endoscopic findings, and overall health. “Induction” refers to the initial treatment period aimed at quickly reducing inflammation, while “maintenance” means the ongoing treatment intended to keep the disease under control. Participants will have routine check‑ups, blood tests, and questionnaires to monitor safety and how well the medication works.

Participants in the study will be randomly assigned to receive either Fenebrutinib, Teriflunomide, or a placebo. A placebo is a substance with no active medication, used to compare the effects of the actual drugs being tested. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment, to ensure unbiased results. The trial will last for a period of time during which participants will take the medication orally, and their health will be monitored regularly to assess the impact of the treatment on their condition.

The main goal of the study is to determine how well Fenebrutinib works in reducing the annualized relapse rate, which is the average number of relapses a patient experiences in a year. Additionally, the study will look at other factors such as changes in brain volume, the number of new or enlarging lesions detected by MRI scans, and any side effects experienced by participants. This research is important for understanding the potential benefits and risks of Fenebrutinib as a treatment option for people living with RMS.

The purpose of the study is to evaluate whether Orelabrutinib can delay the worsening of disability compared with placebo. Participants will receive the assigned tablet each day for several years and will attend regular clinic visits where their ability to perform everyday tasks is checked and brain scans using MRI are performed to look for new lesions. The study will track how long it takes before a confirmed increase in disability occurs and will record any safety concerns throughout the trial.

The purpose of the study is to evaluate how well AVP-786 works in reducing agitation symptoms in patients with Alzheimer’s-related dementia. Participants in the study will receive either the AVP-786 capsules or a placebo, and neither the participants nor the researchers will know which treatment each participant is receiving. This is known as a double-blind study. The study will take place over a period of time, during which participants will be monitored for changes in their symptoms and any side effects they may experience.

Throughout the study, participants will be asked to take the medication orally, in capsule form, and will be regularly assessed by healthcare professionals. The study aims to provide valuable information on whether AVP-786 can be a beneficial treatment option for managing agitation in patients with Alzheimer’s disease. The results will help determine if this medication can improve the quality of life for those affected by this condition.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

People in the study are assigned by chance to receive either orelabrutinib or placebo. The study is set up so that neither the participants nor the study doctors know which treatment is being given during the trial. Treatment is taken over time, and the study follows participants to see how their condition changes during the study period.

PPMS can affect walking, balance, hand use, and other body functions. Disability progression means a gradual increase in these problems. The study is designed to compare how often this worsening happens in the two groups.

The main goal is to assess the long‑term safety and tolerability of the medicine, meaning researchers will watch for any side effects or problems over an extended period. After the initial treatment period, participants will continue to attend regular visits where doctors will ask about health changes, perform a simple nasal examination, and may take a small blood sample to check drug levels. The study also records whether participants need additional treatments such as a short course of a systemic corticosteroid (a pill that reduces inflammation throughout the body) or sinus surgery.

The purpose of the study is to assess whether RO7790121 can help patients achieve clinical remission, which means a significant reduction in disease activity, and an endoscopic response, which refers to visible improvements in the digestive tract as seen through an endoscope. Participants in the study will receive either the treatment or a placebo, and their progress will be monitored over time to see how well the treatment works in reducing symptoms and improving their condition.

Throughout the study, researchers will track various outcomes, such as the overall change in symptoms, the severity of symptoms, and the general well-being of participants. They will also monitor any adverse events, which are unwanted effects that might occur during the trial. The study aims to provide valuable information on the potential benefits and risks of using RO7790121 for treating Crohn’s Disease, helping to improve future treatment options for those affected by this condition.

Participants in the study will be randomly assigned to receive either BHV-7000 or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for about eight weeks, during which participants will take the medication or placebo daily. Researchers will monitor the participants to see if there is a reduction in the number of seizures they experience. The goal is to find out if BHV-7000 can help reduce seizures by at least 50% in those taking the medication compared to those taking the placebo.

Throughout the study, the safety and tolerability of BHV-7000 will be closely observed. This means researchers will keep track of any side effects or adverse reactions participants might experience. The study aims to provide valuable information on whether BHV-7000 can be a beneficial treatment option for people with Refractory Focal Onset Epilepsy, potentially offering a new way to manage this challenging condition.

The purpose of this study is to determine if remibrutinib is more effective than teriflunomide in reducing the frequency of relapses in people with relapsing forms of MS. Participants in the study will be randomly assigned to receive either remibrutinib, teriflunomide, or a placebo, which is a substance with no active medication. The study will begin with a period where participants receive either remibrutinib or teriflunomide, followed by an extended treatment phase where all participants will receive remibrutinib. This approach helps researchers understand the long-term effects of remibrutinib on MS.

Throughout the study, participants will take the medications orally, and their health will be monitored regularly to assess the impact of the treatments. The study aims to provide valuable information on how well remibrutinib works compared to teriflunomide and to ensure the safety of participants. By participating in this study, researchers hope to find a more effective treatment option for those living with relapsing MS.

Participants in the study will receive either Satralizumab or a placebo. Satralizumab is administered as a subcutaneous injection, which means it is injected under the skin. The study will last for a period of 48 weeks, during which participants will be monitored for changes in their symptoms, such as a reduction in eye bulging and improvements in eye function and appearance. The study will also assess the safety of Satralizumab by monitoring any side effects that may occur.

In addition to Satralizumab, the study will also involve other medications, including Azathioprine, Mycophenolate Mofetil, Tocilizumab, Rituximab, Ciclosporin, and Glucocorticoids. These medications are commonly used to manage immune system activity and inflammation. The study aims to provide valuable information on the potential benefits and risks of using Satralizumab for treating Moderate-to-Severe Thyroid Eye Disease, helping to improve the quality of life for those affected by this condition.

The purpose of this study is to assess how well XEN1101 works in reducing the number of seizures experienced by participants. Participants will be randomly assigned to receive either XEN1101 or a placebo. The study will last for a period of 12 weeks, during which participants will take the capsules daily. Throughout the study, participants will be monitored to see if there is a reduction in the frequency of their seizures and to evaluate the safety and tolerability of the medication.

This trial is designed to provide valuable information on the potential benefits of XEN1101 as an additional treatment for people with focal onset seizures. The results will help determine if XEN1101 can be an effective option for managing this type of epilepsy. Participants will be required to keep a diary of their seizures to help researchers understand the impact of the treatment. The study aims to contribute to the development of new therapies for individuals living with epilepsy.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

The purpose is to determine if using both medications together works better than empagliflozin alone in preventing serious heart-related health issues in people with these three conditions. The study will particularly look at how well this combination prevents death from heart problems and reduces the need for hospital visits due to heart failure.

Participants in this study will receive treatment for about 51 months. During this time, they will take either the combination of both medicines or empagliflozin with a placebo. Their blood pressure, kidney function, and heart health will be monitored throughout the study period. The medications being tested are designed to help manage blood sugar levels and blood pressure while protecting the heart and blood vessels.

The purpose of the study is to compare the effectiveness of different medication combinations in preventing the cancer from getting worse. One group will receive a combination of sotorasib, panitumumab, and FOLFIRI. FOLFIRI is a treatment plan that includes fluorouracil, irinotecan hydrochloride trihydrate, and calcium folinate, all of which are administered through intravenous use, meaning they are delivered directly into a vein. Another group will receive FOLFIRI either alone or combined with bevacizumab.

Participants will be assigned to one of these treatment groups to see which approach is better at managing the disease. The study will follow the progress of the cancer over time to observe how long the treatments keep the disease from spreading further or increasing in size.

Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

The purpose of this study is to find out whether zilebesiran can reduce the risk of serious heart-related problems compared to placebo when added to standard blood pressure treatment. The study will look at whether the medication can prevent major events such as death from heart problems, heart attacks, strokes, or episodes of heart failure that require urgent medical attention or hospital admission. Heart failure is a condition where the heart cannot pump blood effectively enough to meet the body’s needs.

During the study, participants will receive injections of either zilebesiran or placebo while continuing their regular blood pressure medications. The study will measure blood pressure readings at regular visits and will track any heart-related health events that occur over time. Participants will be followed for several years to determine whether the treatment helps prevent serious cardiovascular problems. The study will also monitor how well the medication lowers blood pressure and whether it affects the risk of different types of heart and blood vessel complications.

During the study, people will receive different doses of RO7268489 or placebo in addition to their regular ocrelizumab treatment. The study will look at how well the medication works by checking if disability gets worse over time. This will be measured by looking at walking ability, hand function, and thinking skills. The study will also check how safe the medication is by watching for any unwanted effects and by doing regular health checks including blood tests and heart monitoring.

People taking part will need to wear a device that measures how they walk. The study will also measure the levels of certain substances in the blood to understand how the medication works in the body. The study will last for several years and will compare the results between people taking RO7268489 and those taking placebo to determine if the medication is helpful in slowing down the progression of multiple sclerosis.

The purpose of this research is to determine if using these clot-dissolving medications leads to better recovery in stroke patients who are already taking blood-thinning medicines. The medications will be compared to standard care treatment to see if they can improve patients’ ability to perform daily activities after their stroke.

During the study, participants will receive either one of the clot-dissolving medications or standard care treatment. The treatment must be given within 4.5 hours of when stroke symptoms begin. Doctors will monitor patients’ recovery and check for any bleeding complications. Follow-up assessments will be conducted over 90 days to evaluate how well patients recover from their stroke.

The study tests whether olpasiran is more effective than a placebo in reducing the risk of serious heart-related events. These events include coronary heart disease death, myocardial infarction (heart attack), and emergency procedures to restore blood flow to the heart. The medication is being studied specifically in people who have high levels of lipoprotein(a) in their blood and are considered at risk for heart problems.

During the study, participants will receive either olpasiran or a placebo while continuing their usual heart medications. The study will track any heart-related events that occur and measure how the treatment affects the amount of lipoprotein(a) in the blood. This research is part of a larger program called OCEAN(a)-PreEvent, which aims to better understand how to prevent first-time heart problems in people with high lipoprotein(a) levels.

The medication is given as a solution for injection under the skin (subcutaneous use). During the study, participants will receive either maridebart cafraglutide or placebo. The study will track important heart-related events that may occur, such as heart attacks, strokes, and the need for heart procedures.

The research team will monitor participants’ health throughout the study, focusing particularly on heart and blood vessel-related events. The study will look at whether the medication can help prevent serious heart problems and improve survival rates in people who have both cardiovascular disease and weight issues.

The purpose of the study is to evaluate how well olezarsen works in reducing the levels of fasting triglycerides from the start of the study. Participants will receive either olezarsen or a placebo and will be monitored over a period of time to see how their triglyceride levels change. The study will also look at other factors, such as changes in certain proteins and cholesterol levels, and the occurrence of any related health events.

Participants in the study will be required to follow a specific diet and lifestyle, and they will continue their current lipid-lowering therapy, which is a treatment to help manage fat levels in the blood. The study will last for about 53 weeks, during which time participants will have regular check-ups to monitor their health and the effects of the treatment. The goal is to determine if olezarsen can effectively lower triglyceride levels and improve overall health outcomes for those with severe hypertriglyceridemia.

The purpose of this research is to determine how well RO7790121 works compared to placebo in helping patients maintain improvement of their Crohn’s Disease symptoms. The study involves two phases – an initial treatment phase (induction) followed by a longer maintenance phase where patients continue receiving either the study medication or placebo.

During the study, participants will receive regular doses of either RO7790121 or placebo through injections under the skin. The study is “double-blind,” which means neither the patients nor their doctors will know which treatment is being given. The effectiveness of the treatment will be measured by checking if patients achieve reduced disease activity and healing of the intestinal lining.

The purpose of the study is to evaluate the safety of BI 456906 in terms of heart health compared to a placebo. Participants will receive either the treatment or a placebo and will be monitored over time to see if there are any differences in the occurrence of heart-related events such as heart attacks, strokes, or heart failure. The study will also look at changes in body weight, blood pressure, and other health markers over a period of time.

Participants in the study will be followed for several weeks, with regular check-ups to monitor their health and any changes that occur. The study aims to provide valuable information on whether BI 456906 is a safe and effective treatment option for people with obesity and related health conditions. The results could help improve the management of obesity and its complications in the future.

The purpose of the study is to evaluate how effective itepekimab is in reducing the size of nasal polyps and relieving nasal congestion compared to a placebo. Participants in the study will receive either itepekimab or a placebo through a subcutaneous injection, which means the medication is injected under the skin. The study will last for 52 weeks, during which participants will be monitored for changes in their symptoms and any side effects they might experience.

Throughout the study, participants will undergo various assessments to track their progress. These assessments will include checking the size of the nasal polyps and the level of nasal congestion. The study will also look at other symptoms like loss of smell and sinus opacification, which refers to the cloudiness seen in the sinuses on a computed tomography (CT) scan. The trial aims to provide valuable information on the safety and effectiveness of itepekimab for people with chronic rhinosinusitis with nasal polyps.

The purpose of the study is to determine how effective Tolebrutinib is in slowing down the progression of disability in individuals with PPMS. Participants in the study will be randomly assigned to receive either Tolebrutinib or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased and reliable.

Throughout the study, participants will be monitored for changes in their condition, including any progression of disability. The study will also look at other factors such as changes in brain volume, cognitive function, and overall quality of life. Safety and tolerability of the medication will be closely observed to ensure the well-being of all participants. The study aims to provide valuable information on whether Tolebrutinib can be a beneficial treatment option for those living with PPMS.

The purpose of this study is to evaluate how well ofatumumab is tolerated and how safe it is when used over a long period. Participants in the study will receive ofatumumab as an injection under the skin once every four weeks. The study will monitor participants for any side effects or changes in their health, including any changes in their laboratory test results or vital signs. The study will also track the number of relapses participants experience and any changes in their level of disability over time.

Participants will be followed for up to 240 weeks, which is about 4.5 years, to gather comprehensive data on the long-term effects of ofatumumab. The study aims to provide valuable information on the potential benefits and risks of using ofatumumab for managing relapsing multiple sclerosis, helping to inform future treatment options for this condition.

The trial is designed to be conducted in two phases. In the first phase, the focus is on assessing the clinical efficacy, which means how well the medication works in reducing the symptoms of Crohn’s disease. The second phase will look at both clinical and endoscopic efficacy, which involves using a camera to examine the inside of the digestive tract to see how the medication affects the inflammation. Participants will receive the treatment over a period of time, and their progress will be monitored to gather information on the medication’s safety and effectiveness.

Throughout the study, participants will receive injections of Guselkumab or Ustekinumab, or a placebo, and their health will be closely monitored by healthcare professionals. The study will help determine if Guselkumab can be a beneficial treatment option for people with Crohn’s disease, providing valuable insights into managing this challenging condition. The trial is expected to continue until 2027, allowing researchers to collect comprehensive data on the long-term effects of the treatment.

Participants in the study will receive the medication BHV-7000 over a period of time to see how well it is tolerated and to monitor any side effects. The study will also include a comparison with a placebo to better understand the effects of the medication. The trial is designed to be long-term, lasting up to 52 weeks, to gather comprehensive data on the safety of the treatment.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to collect information on any changes in their condition. The ultimate goal is to determine if BHV-7000 can be a safe and effective treatment option for individuals with refractory focal onset epilepsy, potentially offering a new avenue for managing this challenging condition.

Participants in the study will receive either the BHV-7000 tablet or a placebo. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. The trial will include an open-label extension, which means that after the initial phase, all participants may have the opportunity to receive BHV-7000 if they choose to continue. The study will last for a period of up to 72 weeks.

The main goal is to observe the time it takes for participants to experience a second day with a generalized tonic-clonic seizure during the double-blind phase. Additionally, the study will assess the safety and tolerability of BHV-7000 by monitoring any side effects or adverse events that occur. This trial aims to provide valuable information on the potential benefits and risks of using BHV-7000 as a treatment option for individuals with this form of epilepsy.

The purpose of the study is to see if the combination of Bemarituzumab and chemotherapy can improve the overall survival of patients with this type of cancer. Participants in the study will receive either the new treatment or the placebo, and their health will be monitored over time to assess the treatment’s effectiveness. The study will involve regular check-ups and assessments to track the progress of the disease and any side effects from the treatment.

Throughout the study, participants will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The trial aims to provide valuable information on whether this new treatment can offer better outcomes for patients with Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpression. The study is expected to continue until 2025, allowing researchers to gather comprehensive data on the treatment’s impact.

Participants in the study will receive either the combination of Apalutamide, radiotherapy, and LHRH agonist or just radiotherapy and LHRH agonist. The study will also include an observational group to gather additional information. Apalutamide is taken as a tablet by mouth, while radiotherapy is a treatment that uses high-energy rays to target cancer cells. The LHRH agonist is a type of hormone therapy that is given as an injection under the skin. The study will monitor participants over a period to observe the effects of the treatments.

The study aims to provide valuable insights into whether adding Apalutamide can improve outcomes for patients with high-risk hormone-sensitive prostate cancer. By using PSMA-PET, a type of imaging that helps visualize prostate cancer, researchers hope to better understand how the cancer responds to the treatment. This trial is an important step in exploring new ways to manage and treat prostate cancer effectively.

Participants in this study will receive tolebrutinib, which is taken as a film-coated tablet, or a placebo. The study will also involve the use of another medication called Aubagio, which contains the active substance teriflunomide. Some participants may receive a placebo that matches the appearance of Aubagio. The study will monitor participants for any side effects or adverse events that may occur while taking these medications. Additionally, the study will track changes in the participants’ condition, such as the progression of disability or the rate of relapses in those with RMS.

The study will last for several years, allowing researchers to gather comprehensive data on the long-term effects of tolebrutinib. Participants will be regularly assessed to ensure their safety and to evaluate the effectiveness of the treatment. The study aims to provide valuable insights into the management of multiple sclerosis and to improve treatment options for those living with this condition.

The purpose of the study is to evaluate how effective the combination therapy is compared to using Guselkumab or Golimumab alone. Participants in the study will receive either the combination therapy, one of the individual treatments, or a placebo. The study will last for about 48 weeks, during which the participants’ health and response to the treatment will be monitored closely.

Throughout the study, participants will have regular check-ups to assess their condition and any changes in their symptoms. The goal is to see if the combination therapy can lead to clinical remission, which means a significant reduction in symptoms, and an endoscopic response, which is an improvement seen during an examination of the digestive tract. This study aims to provide new insights into the treatment of Crohn’s disease and potentially offer a more effective therapy option for those affected by this condition.

The purpose of the study is to assess how well the combination therapy works over a period of 48 weeks compared to using each medication alone. Participants will receive either the combination therapy, one of the medications alone, or a placebo. The study will monitor the participants’ health and response to the treatment throughout this period. The goal is to determine if the combination therapy can lead to clinical remission, which means a significant reduction or disappearance of symptoms, by the end of the study.

Participants in the study will receive their treatments through subcutaneous injections, which means the medication is injected under the skin. The study will use a device called the UltraSafe Plus™ Passive Needle Guard to help with self-injection and ensure safety during the process. This trial aims to provide valuable information on the potential benefits of combining Guselkumab and Golimumab for people living with Ulcerative Colitis.

Participants in the study will receive either Risankizumab or a placebo. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased. The study will last for 52 weeks, during which the participants’ health and response to the treatment will be closely monitored. After this period, there is an option for an open-label extension, where all participants can receive Risankizumab to further assess its long-term safety and effectiveness.

The purpose of this study is to gather more information about how well Risankizumab works in maintaining the health of people with Crohn’s Disease and to ensure its safety over a longer period. This research could potentially lead to better treatment options for those living with this challenging condition.

Participants in the study will be those who have been recently hospitalized with heart failure and have a certain level of heart function, measured by something called the ejection fraction. This is a percentage that shows how well the heart is pumping blood. The study will involve taking the medication or placebo for a period of time, and researchers will monitor the participants for any heart-related events or changes in their condition.

The study aims to gather information on the effectiveness and safety of finerenone in managing heart failure symptoms and improving survival rates. By comparing the outcomes of those taking finerenone with those taking a placebo, researchers hope to better understand the potential benefits of this treatment for patients with heart failure.

The study will test inclisiran, given as an injection under the skin, against placebo while participants continue taking their usual cholesterol-lowering medications. These medications include either atorvastatin (40 mg daily) or rosuvastatin (20 mg or more daily), which belong to a group of drugs called statins that help lower cholesterol levels in the blood.

During the study, which will last for 72 months, participants will receive regular injections of either inclisiran or placebo along with their daily statin medication. The researchers will monitor participants to see if the combination of treatments helps prevent serious cardiovascular events like heart attacks and strokes.